Last reviewed · How we verify
UCB Mesenchymal Stem Cells treatment
At a glance
| Generic name | UCB Mesenchymal Stem Cells treatment |
|---|---|
| Sponsor | Chinese PLA General Hospital |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Pyrexia
- Otitis media
- Fall
- Hand-foot-and-mouth disease
- Laboratory test abnormal
- Strabismus correction
- Infusion related reaction
- Hypoacusis
- Constipation
- Diarrhoea
- Vomiting
- Fatigue
Key clinical trials
- Mechanisms of Treatment Effects Using Cultured, Allogeneic Mesenchymal Stromal Stem Cells (MSCs) in Knee Osteoarthritis (NA)
- Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs (PHASE1, PHASE2)
- Clinical Study of UCB Combined With UC-MSCs in the Treatment of Bone Marrow Failure Disorders (PHASE1, PHASE2)
- A Study of UCB and MSCs in Children With CP: ACCeNT-CP (PHASE1, PHASE2)
- Intra-Osseous Co-Transplant of UCB and hMSC (EARLY_PHASE1)
- Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis (PHASE1)
- Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD) (PHASE1, PHASE2)
- Long-term Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: